Intellia Therapeutics Operating Expenses Growth & History (NTLA)
Intellia Therapeutics's operating expenses was $508.7M for fiscal 2025.
View full Intellia Therapeutics company overviewIntellia Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $508.7M | −$83.5M | −14.10% |
| 2024 | 2024-12-31 | $592.1M | $40.6M | +7.36% |
| 2023 | 2023-12-31 | $551.6M | $41.3M | +8.09% |
| 2022 | 2022-12-31 | $510.3M | $209.4M | +69.58% |
| 2021 | 2021-12-31 | $300.9M | $106.3M | +54.64% |
| 2020 | 2020-12-31 | $194.6M | $45.1M | +30.18% |
| 2019 | 2019-12-31 | $149.5M | $28.2M | +23.22% |
| 2018 | 2018-12-31 | $121.3M | $25.6M | +26.79% |
| 2017 | 2017-12-31 | $95.7M | $47.0M | +96.70% |
| 2016 | 2016-12-31 | $48.6M | — | — |
Intellia Therapeutics quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $120.4M | −$3.8M | −3.08% |
| Q1 2026 | 2026-03-31 | $115.6M | −$21.9M | −15.90% |
| Q4 2025 | 2025-12-31 | $121.7M | −$27.6M | −18.48% |
| Q3 2025 | 2025-09-30 | $125.3M | −$28.6M | −18.60% |
| Q2 2025 | 2025-06-30 | $124.2M | −$21.8M | −14.90% |
| Q1 2025 | 2025-03-31 | $137.4M | −$5.5M | −3.85% |
| Q4 2024 | 2024-12-31 | $149.3M | $11.3M | +8.22% |
| Q3 2024 | 2024-09-30 | $153.9M | $10.8M | +7.53% |
| Q2 2024 | 2024-06-30 | $146.0M | $72,000 | +0.05% |
| Q1 2024 | 2024-03-31 | $142.9M | $18.4M | +14.75% |
| Q4 2023 | 2023-12-31 | $138.0M | $14.3M | +11.58% |
| Q3 2023 | 2023-09-30 | $143.1M | $24.3M | +20.46% |
| Q2 2023 | 2023-06-30 | $145.9M | $33.6M | +29.91% |
| Q1 2023 | 2023-03-31 | $124.6M | −$30.9M | −19.89% |
| Q4 2022 | 2022-12-31 | $123.7M | $30.4M | +32.58% |
| Q3 2022 | 2022-09-30 | $118.8M | $39.6M | +50.00% |
| Q2 2022 | 2022-06-30 | $112.3M | $36.8M | +48.65% |
| Q1 2022 | 2022-03-31 | $155.5M | $102.6M | +194.11% |
| Q4 2021 | 2021-12-31 | $93.3M | $44.3M | +90.37% |
| Q3 2021 | 2021-09-30 | $79.2M | $28.9M | +57.38% |
| Q2 2021 | 2021-06-30 | $75.6M | $26.3M | +53.29% |
| Q1 2021 | 2021-03-31 | $52.9M | $6.9M | +15.02% |
| Q4 2020 | 2020-12-31 | $49.0M | $8.3M | +20.36% |
| Q3 2020 | 2020-09-30 | $50.3M | $14.4M | +40.00% |
| Q2 2020 | 2020-06-30 | $49.3M | $10.7M | +27.79% |
| Q1 2020 | 2020-03-31 | $46.0M | $11.7M | +34.23% |
| Q4 2019 | 2019-12-31 | $40.7M | $12.1M | +42.20% |
| Q3 2019 | 2019-09-30 | $35.9M | $4.4M | +14.08% |
| Q2 2019 | 2019-06-30 | $38.6M | $7.3M | +23.36% |
| Q1 2019 | 2019-03-31 | $34.2M | $4.3M | +14.53% |
| Q4 2018 | 2018-12-31 | $28.6M | −$2.8M | −8.79% |
| Q3 2018 | 2018-09-30 | $31.5M | $8.3M | +35.85% |
| Q2 2018 | 2018-06-30 | $31.3M | $9.3M | +42.57% |
| Q1 2018 | 2018-03-31 | $29.9M | $10.7M | +56.02% |
| Q4 2017 | 2017-12-31 | $31.4M | — | — |
| Q3 2017 | 2017-09-30 | $23.2M | — | — |
| Q2 2017 | 2017-06-30 | $21.9M | — | — |
| Q1 2017 | 2017-03-31 | $19.2M | — | — |
Intellia Therapeutics operating expenses trends
Over the last five fiscal years, Intellia Therapeutics's operating expenses increased from $194.6M to $508.7M, a change of $314.1M. The latest reported quarter, Q2 2026, shows $120.4M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Intellia Therapeutics source filings ↗